Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Ixazomib is a novel oral proteosome inhibitor approved in combination with lenalidomide and dexamethasome for the treatment of relapsed/refractory multiple myeloma. Here, Rakesh Popat, MD, PhD from the University College London, London, UK talks about the real world data presented at European Hematology Association (EHA) 2017 meeting.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.